| 薛 辉,辛凤池,穆素恩,杨 俭,赵树巧.血清胃蛋白酶原联合G-17对萎缩性胃炎及胃癌早期诊断价值[J].,2017,17(11):2119-2122 |
| 血清胃蛋白酶原联合G-17对萎缩性胃炎及胃癌早期诊断价值 |
| Early Diagnosis Value of Serum Pepsinogen Combined with G-17 for Atrophic Gastritis and Gastric Cancer |
| 投稿时间：2016-10-28 修订日期：2016-11-21 |
| DOI：10.13241/j.cnki.pmb.2017.11.031 |
| 中文关键词: 胃蛋白酶原 胃泌素 萎缩性胃炎 胃癌 早期诊断 |
| 英文关键词: Pepsinogens Gastrins Atrophic gastritis Gastric cancer Early diagnosis |
| 基金项目:2014年度石家庄市科学技术研究与发展指导计划项目（141462833） |
|
| 摘要点击次数: 217 |
| 全文下载次数: 115 |
| 中文摘要: |
| 摘要 目的：探索检测血清胃蛋白酶原I（PGI）、胃蛋白酶原II（PGII）、胃泌素-17（G-17）在萎缩性胃炎及胃癌中的诊断价值。方法：收集医院2015年2月至12月门诊及住院的慢性非萎缩性胃炎44例（非萎缩性胃炎组），慢性萎缩性胃炎47例（萎缩性胃炎组），早期胃癌42例（胃癌组）。采用酶联免疫吸附试验（ELISA）测定各组血清PGI、PGII、G-17的水平，同时计算PGI/PGII的比值（PGR），比较各组指标间的差异，同时绘制各指标筛查萎缩性胃炎及胃癌的受试者工作曲线（ROC）曲线，分别评价其诊断价值。结果：胃癌组及萎缩性胃炎组的血清PGI、PGR水平较非萎缩性胃炎组明显下降，且胃癌组下降更明显，差异均具有统计学意义（P<0.05），萎缩性胃炎组血清PGII显著低于非萎缩性胃炎组，差异均具有统计学意义（P<0.05）；胃癌组的血清G-17水平较非萎缩性胃炎组及萎缩性胃炎组均升高，差异有统计学意义（P<0.05）。血清PGI筛查萎缩性胃炎的最佳界值为PGI<90 ng/mL，其灵敏度和特异度分别为71.5%和51.0%，血清PGR筛查萎缩性胃炎的最佳界值为PGR<8，其灵敏度和特异度分别为71.9%和54.0%，血清G-17筛查萎缩性胃炎的最佳界值为G-17<5 pmol/L，其灵敏度和特异度分别为66.1%和64.0%。血清PGI筛查胃癌的最佳界值为PGI<73 ng/mL，其灵敏度和特异度分别为86.0%和74.9%；血清PGR筛查胃癌的最佳界值为PGR<3，其灵敏度和特异度分别为90.2%和62.5%；血清G-17筛查胃癌的最佳界值为G-17<4 pmol/L，其灵敏度和特异度分别为62.5%和61.3%。结论：胃癌及萎缩性胃炎患者血清PGI、PGR水平下降明显，且胃癌患者的血清G-17异常升高，血清PG联合GS-17测定可用于萎缩性胃炎及胃癌的早期筛查。 |
| 英文摘要: |
| ABSTRACT Objective: To research the diagnostic value of measuring serum pepsinogen I(PGI),pepsinogen II(PGII) and gastrin-17 (G-17) for atrophic gastritis and gastric cancer. Methods: A total of 44 patients were diagnosed with non-atrophic gastritis(non-atrophic gastritis group), 47 patients were chronic atrophic gastritis(atrophic gastritis group),42 were gastric cancer(gastric cancer group)were en- rolled in the hospital February 2015 to December 2015.The serum PGI, PGII and G-17 levels were detected by enzyme-linked im- munosorbent assay (ELISA), and PGI/II ratio (PGR) was calculated, compared above indexes in different groups, and drew the receiver operating curve (ROC) of above indexes, and analyzed their diagnostic value. Results: The levels of serum PGI and PGR in gastric cancer group and chronic atrophic gastritis group were significantly decreased than that of non-atrophic gastritis group, and gastric cancer group decreased more, the differences were statistically significant (P<0.05), the level of PGII in atrophic gastritis group was lower than non-at- rophic gastritis group, the difference was statistically significant (P<0.05), the level of serum G-17 in gastric cancer were significantly in- creased than chronic atrophic gastritis and non-atrophic gastritis group, the differences were statistically significant (P<0.05). The opti- mal value of PGI screening for atrophic gastritis was PGI<90 ng/mL, its sensitivity and specificity were 71.5% and 51.0%, respectively.The optimal value of PGR screening for atrophic gastritis was PGR<8, its sensitivity and specificity were 71.9% and 54.0%, respectively.The optimal value of G-17 screening for atrophic gastritis was G-17<5 pmol/L, its sensitivity and specificity were 66.1% and 64.0%, re- spectively. The optimal value of PGI screening for gastric cancer was PGI<73 ng/mL, its sensitivity and specificity were 86.0% and 74.9%, respectively. The optimal value of PGR screening for gastric cancer was PGR<3, its sensitivity and specificity were 90.2% and 62.5%, respectively. The optimal value of G-17 screening for gastric cancer was G-17<4 pmol/L, its sensitivity and specificity were 62.5% and 61.3%, respectively. Conclusion: The levels of serum PGI and PGR in patients with gastric cancer and atrophic gastritis are significantly decreased, and the serum G-17 of the patients with gastric cancer are abnormally increased, detecting serum PG combined with G-17 can be used to screen early gastric cancer and chronic atrophic gastritis. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
